Form 4: Precision BioSciences CFO John Alexander Kelly Reports Stock Vesting

John Alexander Kelly, CFO of Precision BioSciences, reports the vesting and settlement of Restricted Stock Units (RSUs) on June 7, 2024.

Summary

• On June 7, 2024, John Alexander Kelly, the Chief Financial Officer of Precision BioSciences, reported the vesting and settlement of 454 Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of Precision BioSciences' Common Stock each.
• The RSUs were granted on June 7, 2021, and vested in three substantially equal annual installments, completing on June 7, 2024.
• Following the reported transaction, Kelly directly owns 31,468 shares of Common Stock.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing indicating routine vesting of stock options. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The vesting of RSUs indicates continued service and commitment of the CFO to the company.

Future Outlook

NA

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the holdings of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency regarding insider transactions.
• Executive compensation packages often include stock options and RSUs to align management's interests with those of shareholders.
• The vesting schedule of the RSUs (three annual installments) is a common structure.

Stakeholder Impact

• The vesting of RSUs aligns the CFO's interests with those of shareholders.

Key Dates